Impact of Proteinuria and Declining Kidney Function on the Healthcare Resource Utilization and Associated Costs of Patients With IgA Nephropathy: A Retrospective Analysis in the UK and Spain
Author(s)
Garth Baxter, BSc1, Antonio Ramirez de Arellano Serna, MSc, DPhil2, Sonali Dasgupta, BSc3, Joseph Imperato, BSc3.
1Vifor Pharma Group, Staines-upon-Thames, United Kingdom, 2Director HEOR, CSL Vifor, Glattbrugg, Switzerland, 3IQVIA, Durham, NC, USA.
1Vifor Pharma Group, Staines-upon-Thames, United Kingdom, 2Director HEOR, CSL Vifor, Glattbrugg, Switzerland, 3IQVIA, Durham, NC, USA.
OBJECTIVES: Immunoglobulin A nephropathy (IgAN) is a leading cause of chronic kidney disease (CKD); condition management has a substantial economic burden, through high healthcare resource utilisation (HCRU) and costs. This study describes the impact of proteinuria and CKD stage on HCRU and associated costs in the United Kingdom (UK) and Spain.
METHODS: This retrospective, descriptive analysis included patients of any age with recorded nephritis/nephropathy (International Classification of Diseases [ICD]-9 583.9) and/or recurrent or persistent haematuria (ICD-10 N02.8/N02.9) between October 2015 and October 2022, allowing for ≥1 year follow-up. Stratification was by visit type (inpatient, outpatient, emergency), proteinuria levels (<0.5 g/day, 0.5-<1 g/day, 1-<2 g/day, or ≥2 g/day), and CKD stage (derived from ICD-10 codes and estimated glomerular filtration rate). HCRU data were obtained from TriNetX’s electronic medical record database. Costs from national healthcare databases or published literature for 2020-2022 were adjusted for inflation to 2023 values.
RESULTS: IgAN prevalence (N) in the UK and Spain was 6940 and 1080, respectively. The average number of outpatient visits per patient was higher in those with increased proteinuria levels (<0.5 g/day vs ≥2 g/day) for both the UK (6.1 to 8.6) and Spain (14.8 to 21.3). Inpatient visits also increased in the UK (3.6 to 6.3), while Spain remained unchanged (2.1 to 2.0). For all visits, mean total cost per patient increased with proteinuria levels, from £2,820.77 (<0.5 g/day) to £23,507.50 (≥2 g/day) in the UK, and from €1,945.03 to €7,974.31 in Spain. Average total costs for CKD stages by proteinuria levels were lower for CKD stage 1 & 2 (UK: £6,460.00; Spain: €4,433.00) compared to CKD stage 5 (UK: £64,910.00; Spain: €58,968.89).
CONCLUSIONS: Increased proteinuria levels and advanced CKD stages among patients with IgAN were associated with increased HCRU and costs in the UK and Spain.
METHODS: This retrospective, descriptive analysis included patients of any age with recorded nephritis/nephropathy (International Classification of Diseases [ICD]-9 583.9) and/or recurrent or persistent haematuria (ICD-10 N02.8/N02.9) between October 2015 and October 2022, allowing for ≥1 year follow-up. Stratification was by visit type (inpatient, outpatient, emergency), proteinuria levels (<0.5 g/day, 0.5-<1 g/day, 1-<2 g/day, or ≥2 g/day), and CKD stage (derived from ICD-10 codes and estimated glomerular filtration rate). HCRU data were obtained from TriNetX’s electronic medical record database. Costs from national healthcare databases or published literature for 2020-2022 were adjusted for inflation to 2023 values.
RESULTS: IgAN prevalence (N) in the UK and Spain was 6940 and 1080, respectively. The average number of outpatient visits per patient was higher in those with increased proteinuria levels (<0.5 g/day vs ≥2 g/day) for both the UK (6.1 to 8.6) and Spain (14.8 to 21.3). Inpatient visits also increased in the UK (3.6 to 6.3), while Spain remained unchanged (2.1 to 2.0). For all visits, mean total cost per patient increased with proteinuria levels, from £2,820.77 (<0.5 g/day) to £23,507.50 (≥2 g/day) in the UK, and from €1,945.03 to €7,974.31 in Spain. Average total costs for CKD stages by proteinuria levels were lower for CKD stage 1 & 2 (UK: £6,460.00; Spain: €4,433.00) compared to CKD stage 5 (UK: £64,910.00; Spain: €58,968.89).
CONCLUSIONS: Increased proteinuria levels and advanced CKD stages among patients with IgAN were associated with increased HCRU and costs in the UK and Spain.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE540
Topic
Economic Evaluation
Disease
Rare & Orphan Diseases, Urinary/Kidney Disorders